Marrone Bio Innovations WKN: A1W30B ISIN: US57165B1061 Kürzel: 0MB Branche:

👌

.

👀

schaut bullish aus - wer ist noch der Meinung

Simon Haimerl CEO

Marrone @simon Haimerl

Marrone to the 🌝

Maronne und 🆎

🚀🚀🚀

Marrone Bio Innovations (NASDAQ:MBII) MBI describes themselves as the only public pure play biologicals company. Over the last few years, the company has teetered on the edge of bankruptcy while developing an extensive pipeline along with escalating revenues improving margins, making a transformative acquisition, adding new partnerships and expanding its global footprint. The company's flagship product has been Regalia, which is a family of fungicides used for enhancement of plant health. Regalia has enjoyed market share leadership and has recently been approved for the Canadian cannabis and hemp market. California cannabis and hemp approval is pending. The company has spent heavily on R&D to develop a strong pipeline and is now implementing its strategy designed for profitability. MBI has a three-tier strategy: Short term - introduce new products. Intermediate term - introduce next generation products. Long term strategy - international expansion. Recent new product developments include EPA approval for Pacesetter in February. Pacesetter improves plants' root systems and is pending approval in individual states that are major wheat and soybean producers. Jet Oxide Sanitizer had been approved for usage beyond fruit and vegetables and has been effective in combating COVD-19 by eliminating the virus on food industry equipment and machinery. Stargus, a new fungicide for plant health has been approved by the EPA as well as gained approval for each U.S. state and territory, as well as Mexico and Canada. MBI claims that combining chemical and biologics creates exponentially better solutions and is introducing a next generation crop protector by partnering with Vive Crop Protection to commercialize Azoxystrobin, a fungicide for wide use in crop protection which is made up of MBI's biologic Regalia and Vive's chemical solution. The Pro Farm acquisition, a Finland-based company, expands MBI's footprint into Europe as well as Latin America where Pro Farm has been active. The company currently has 73 active research projects in Latin America. Research studies are required in each jurisdiction in order to gain registration and approval for commercialization. The stock price has been on a nice uptrend since hitting a COVID-19 inspired bottom in the spring. There are 152.5 million shares outstanding, and the market cap is $181.4 million. MBI reported $10.4 million in cash and $8.9 million in debt as of the end of the second quarter. The EV is $182.9 million. Consensus estimates are for revenue of $60.64 million for 2021, resulting in an EV/Sales ratio of 2.9X, indicating the stock is currently fairly priced in comparison to its peer group. Management is counting on raising $20 million from warrant conversions with strike prices of $0.75 with expiration dates ranging from December 15, 2020, to December 15, 2021, which would be sufficient to carry them into 2022 when profitability is expected. I think that the stock will find new investor support should the possibility of profitability become clearer. Risks include that the active ingredient in Regalia is sourced from one supplier located in China and Pro Farm products are partially sourced from Russia. https://seekingalpha.com/article/4377277-4-microcaps-in-high-mergers-and-acquisitions-agtech-space

http://crweworld.com/article/news-provided-by-globenewswire/1464016/marrone-bio-innovations-jet-oxide-15-sanitizer-product-is-allowed-by-the-us-epa-for-use-on-industrial-hard-surfaces-for-human-coronaviruses

Hab's mir mal angesehen aber bin nicht überzeugt

Hallo, gibt es irgendjemanden hier der investiert ist?